Citi Research reported that Sino Biopharm's (01177.HK) acquisition of Lixun Pharmaceutical will significantly expand its innovative product pipeline.
The note highlights Lixun's valuable assets, including: - LM-299 (PD-1/VEGF) licensed to Merck - LM-305 (GPRC5D ADC) licensed to AstraZeneca - LM-108 (CCR8 monoclonal antibody) - LM-302 (CLDN18.2 ADC)
This transaction represents a landmark in China's pharmaceutical sector as the industry's first major China-to-China acquisition. Citi maintains its "Buy" rating on Sino Biopharm with a HK$6.20 target price.
The research further notes significant progress in Sino Biopharm's innovative drug development: - TQC3721, the world's second-leading PDE3/4 inhibitor, initiated Phase III trials for COPD in June, demonstrating strong out-licensing potential - Pipeline assets including TQB6411 (EGFR/cMet ADC) and TQB3003 (fourth-generation EGFR TKI) have advanced to clinical stages
China's broader pharmaceutical and biotech industry continues to benefit from accelerating innovation and growing licensing trends.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。